Hypertriglyceridemia may be severe in CML patients treated with interferon-alpha.
We analyzed serum triglyceride (TG) levels in 22 chronic myeloid leukemia (CML) patients treated with interferon-alpha (IFN-alpha). Hypertriglyceridemia was present in one-half of patients at diagnosis, and IFN-alpha treatment was associated with a further increase in 90% of the total group of patients. This increase was maximal during the first months of therapy. Four patients (18%) reached levels higher than 1,000 mg/dl. This is the first report describing this secondary effect in CML patients treated with IFN-alpha.
Peñarrubia
M J
MJ
Hematology Department, Hospital de la Princesa, Madrid, Spain.
Steegmann
J L
JL
Lavilla
E
E
Casado
F
F
Requena
M J
MJ
Picó
M
M
Arranz
R
R
Fernández-Rañada
J M
JM
D000293:Adolescent; D000328:Adult; D016632:Apolipoprotein A-I / Q000378:metabolism; D001055:Apolipoproteins B / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D006801:Humans; D015228:Hypertriglyceridemia / Q000209:etiology*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000628:therapy*; D008875:Middle Aged; D011994:Recombinant Proteins
D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins